9,282 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,282 shares of the company’s stock, valued at approximately $1,315,000.

Several other hedge funds also recently made changes to their positions in NBIX. AQR Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after buying an additional 1,263,633 shares during the period. UBS Group AG increased its stake in shares of Neurocrine Biosciences by 169.8% in the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock worth $139,494,000 after buying an additional 618,956 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Neurocrine Biosciences by 11.0% in the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after buying an additional 468,405 shares during the period. Two Sigma Investments LP purchased a new position in shares of Neurocrine Biosciences in the third quarter worth $48,791,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Neurocrine Biosciences in the second quarter worth $42,933,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the sale, the director owned 511,293 shares in the company, valued at approximately $78,907,848.69. The trade was a 32.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the sale, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 292,047 shares of company stock worth $45,216,687. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on NBIX shares. Needham & Company LLC reiterated a “buy” rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a report on Monday, April 6th. Guggenheim reiterated a “buy” rating and issued a $175.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Royal Bank Of Canada lifted their price target on shares of Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a report on Friday, May 29th. Citigroup lifted their price target on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $187.52.

Neurocrine Biosciences Trading Down 3.8%

Shares of NBIX stock opened at $154.84 on Wednesday. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $162.39. The stock has a market cap of $15.57 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.21 and a beta of 0.40. The company’s fifty day moving average price is $139.98 and its 200-day moving average price is $139.18.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.